Schedule 13G ownership disclosure
NextCure Inc
Common Stock, par value $0.001 per share · CUSIP: 65343E207
Event date: 2025-06-20
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Simcere Zaiming, Inc.
Shares: 338,636.00 · Class: 12.7%
- Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.
Shares: 338,636.00 · Class: 12.7%
- Hainan Simcere Zaiming Pharmaceutical Co., Ltd.
Shares: 338,636.00 · Class: 12.7%
- Simcere Pharmaceutical Group Limited
Shares: 338,636.00 · Class: 12.7%
- Ren Jinsheng
Shares: 338,636.00 · Class: 12.7%
- Tang Renhong
Shares: 338,636.00 · Class: 12.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-078679
- Form type
- SCHEDULE 13G
- Filer
- NextCure, Inc.
- CIK
- CIK 1661059
- Filed
- Aug 19, 2025
- Reporting period
- Jun 20, 2025
- Description
- Schedule 13G beneficial ownership